Tevogen Bio Holdings Inc.
TVGNHealthcare|Biotechnology|US
$5.59
+0.03 (+0.54%)
Cash / Share
$0.28
Financials
Financial Snapshot
Market Cap
$23.3M
Enterprise Value
$25.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$21.6M
Cash & Investments
$1.1M
Net Cash
-$2.0M
Free Cash Flow (TTM)
-$11.6M
Operating CF (TTM)
-$11.6M
Debt/Equity
-0.34
Cash Runway & Burn Rate
Cash on Hand
$1.1M
Quarterly Burn
$2.9M
Monthly Burn
$964.2K
Est. Runway
~0.4 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $7.1M | $5.5M | $1.1M | $1.3M | $552.4K | $1.1M | |
| Operating Cash Flow | -$5.3M | -$8.7M | -$8.2M | -$12.0M | -$12.3M | -$11.6M | |
| Free Cash Flow | -$5.4M | -$9.1M | -$8.3M | -$12.0M | -$12.4M | -$11.6M | |
| Capital Expenditure | -$109.7K | -$479.0K | -$133.0K | $0.00 | -$64.4K | -$64.4K | |
| Financing Cash Flow | $12.5M | $7.5M | $3.9M | $12.2M | $11.7M | $12.0M |
R&D Spending
R&D (TTM)
$11.6M
R&D Intensity
—
R&D Growth vs Prior
+4.7%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $3.0M | $0.00 | $4.4M | $31.0M | $11.1M | $11.6M | |
| SG&A | $1.7M | $953.1K | $4.1M | $22.1M | $15.0M | $9.8M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $378.4K | $403.6K | $0.00 | $205.0K | |
| Gross Profit | $0.00 | $0.00 | -$378.4K | -$403.6K | $0.00 | -$205.0K | |
| R&D | $3.0M | $0.00 | $4.4M | $31.0M | $11.1M | $11.6M | |
| SG&A | $1.7M | $953.1K | $4.1M | $22.1M | $15.0M | $9.8M | |
| Operating Income | -$4.6M | -$953.1K | -$8.8M | -$53.6M | -$26.1M | -$21.4M | |
| Interest Expense | $598.5K | $0.00 | $256.0K | $184.0K | $195.6K | $160.2K | |
| Pretax Income | -$15.6M | $4.4M | -$60.5M | -$13.7M | -$26.3M | -$21.6M | |
| Net Income | -$15.6M | $4.4M | -$60.5M | -$10.1M | -$26.3M | -$21.6M | |
| EPS (Diluted) | -16.50 | 1.83 | -0.02 | -4.68 | -8.08 | -5.83 | |
| EBITDA | -$15.0M | $4.6M | -$58.9M | -$13.1M | -$25.6M | -$21.0M | |
| Shares Out. (M) | 0.96 | 2.40 | 3.31 | 2.93 | 3.32 | 3.83 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.1M | $5.5M | $1.1M | $1.3M | $552.4K | $1.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $7.2M | $5.8M | $1.7M | $2.4M | $1.5M | $2.0M | |
| Total Assets | $7.7M | $7.7M | $5.5M | $3.5M | $4.4M | $4.7M | |
| Total Current Liabilities | $667.9K | $2.0M | $85.5M | $9.0M | $7.1M | $6.2M | |
| Long-Term Debt | $23.5M | $39.3M | $14.2M | $1.0M | $1.1M | $1.1M | |
| Total Liabilities | $24.1M | $41.7M | $99.9M | $10.1M | $12.6M | $13.6M | |
| Stockholders' Equity | -$16.5M | -$34.0M | -$94.4M | -$6.7M | -$8.2M | -$8.9M | |
| Retained Earnings | -$17.1M | -$39.2M | -$99.7M | -$113.4M | -$139.7M | -$150.9M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.3M | -$8.7M | -$8.2M | -$12.0M | -$12.3M | -$11.6M | |
| Capital Expenditure | -$109.7K | -$479.0K | -$133.0K | $0.00 | -$64.4K | -$64.4K | |
| Free Cash Flow | -$5.4M | -$9.1M | -$8.3M | -$12.0M | -$12.4M | -$11.6M | |
| Investing Cash Flow | -$109.7K | -$479.0K | -$133.0K | $0.00 | -$64.4K | -$64.4K | |
| Financing Cash Flow | $12.5M | $7.5M | $3.9M | $12.2M | $11.7M | $12.0M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $4.9M | $9.0M | |
| Repurchase of Stock | $0.00 | $0.00 | -$343.0M | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $12.5M | $7.5M | $4.0M | $1.0M | $3.4M | $2.0M | |
| Stock Based Comp. | $582.4K | $4.6M | $0.00 | $40.8M | $16.2M | $11.8M | |
| Net Change in Cash | $7.1M | -$1.6M | -$4.4M | $230.6K | -$730.6K | $396.9K |
Dilution Tracker
Shares outstanding grew 246.3% over 5 years — significant dilution
Shares Outstanding
4M
5-Year Share Growth
+246.3%
Stock Issuance (TTM)
$9.0M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.96 | 2.40 | 3.31 | 2.93 | 3.32 | 3.83 | |
| Change vs Prior % | — | 150.3% | 37.9% | -11.3% | 13.2% | 15.3% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $4.9M | $9.0M | |
| Stock Repurchase | $0.00 | $0.00 | -$343.0M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $582.4K | $4.6M | $0.00 | $40.8M | $16.2M | $11.8M |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 94.6% | -13.0% | 64.0% | 151.5% | 319.1% | 248.5% | |
| ROA % | -203.7% | 57.0% | -1098.5% | -292.2% | -599.5% | -457.1% | |
| ROIC % | -66.1% | -15.7% | -892.6% | 1447.3% | 3698.7% | -3850.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -6.7% | 100.0% | |
| Operating Income | 0.0% | 79.4% | -827.8% | -505.7% | 51.2% | |
| Net Income | 0.0% | 128.3% | -1471.9% | 83.3% | -159.8% | |
| EPS (Diluted) | 0.0% | 111.1% | -101.1% | -23300.0% | -72.6% | |
| Operating Cash Flow | 0.0% | -64.1% | 5.6% | -46.8% | -2.7% | |
| Free Cash Flow | 0.0% | -69.6% | 9.1% | -44.5% | -3.3% | |
| R&D Expense | 0.0% | -100.0% | 0.0% | 604.7% | -64.2% | |
| SG&A Expense | 0.0% | -42.7% | 326.1% | 444.9% | -32.1% | |
| Total Assets | 0.0% | 1.1% | -28.9% | -37.1% | 26.6% | |
| Book Value / Share | 0.0% | 17.8% | -101.8% | 92.0% | -9.0% | |
| Debt | 0.0% | 70.4% | 138.5% | -97.0% | 7.5% | |
| Diluted Shares | 0.0% | 150.3% | 37.9% | -11.3% | 13.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-2.41
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.28
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -30.12 | 281.47 | -27825.00 | -11.00 | -2.05 | -0.96 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -28.90 | -36.51 | -19.50 | -22.64 | -6.68 | -2.41 | |
| EV/EBITDA | -32.88 | 274.64 | -32.86 | -11.62 | -2.25 | -1.20 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-59.67
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $502.3M | $1.42B |
| Net Income | -$33.7M | -$43.2M | -$59.7M |
| EPS | $-10.14 | $-13.01 | $-17.97 |
| # Analysts (EPS) | 1 | 1 | 1 |